Market Place
Sourcing Support
I-Mab to Release Q3 2024 Financial Results on November 14, 2024
31 Oct 2024 //
PR NEWSWIRE
I-Mab Presents Givastomig Phase 1 Data at SITC 2024
30 Oct 2024 //
PR NEWSWIRE
I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024
16 Sep 2024 //
PR NEWSWIRE
I-Mab Presents Uliledlimab PK Data At WCLC 2024
10 Sep 2024 //
PR NEWSWIRE
I-Mab To Participate In H.C. Wainwright Global Investment Conference
26 Aug 2024 //
PR NEWSWIRE
I-Mab to Release 1H 2024 Financial Results on August 28, 2024
14 Aug 2024 //
PR NEWSWIRE
I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)
07 Aug 2024 //
PR NEWSWIRE
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
06 Jun 2024 //
PR NEWSWIRE
I-Mab Ragistomig Phase 1: Encouraging Pd-L1X4-1Bb At Asco 2024
23 May 2024 //
GLOBENEWSWIRE
I-MAB Filed 2023 Annual Report on Form 20-F
30 Apr 2024 //
PR NEWSWIRE
I-Mab CEO details considerations behind China split, hints in-licensing
12 Apr 2024 //
ENDPTS
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
05 Apr 2024 //
PR NEWSWIRE
Three more I-Mab execs exit after US/China operations split
02 Apr 2024 //
ENDPTS
I-Mab Reports Full Year 2023 Financial Results and Business Update
14 Mar 2024 //
PR NEWSWIRE
I-Mab divests China business to become US-based biotech firm
09 Feb 2024 //
BIOSPECTRUM ASIA
I-Mab sheds China footprint to transform into US-based biotech
07 Feb 2024 //
FIERCE BIOTECH
I-Mab Announces Participation at Jefferies and Piper Conferences in November
06 Nov 2023 //
PR NEWSWIRE
Felzartamab Granted Breakthrough Therapy Designation by FDA for PMN
02 Nov 2023 //
PR NEWSWIRE
I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio
01 Nov 2023 //
PR NEWSWIRE
I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023
16 Oct 2023 //
PR NEWSWIRE
I-Mab and ABL Bio Announce Latest Updates of Antibody TJ-L14B/ABL503
10 Oct 2023 //
PR NEWSWIRE
AbbVie terminates deal with I-Mab to develop cancer drug
23 Sep 2023 //
REUTERS
I-Mab Announces Upcoming Participation at September Conferences
05 Sep 2023 //
PR NEWSWIRE
I-Mab to seek approval of pediatric growth hormone deficiency drug in China
17 Aug 2023 //
ENDPTS
I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates
17 Aug 2023 //
PR NEWSWIRE
I-Mab to Report Mid-Year 2023 Financial Results
08 Aug 2023 //
PR NEWSWIRE
I-Mab Announce Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig
05 Jul 2023 //
PR NEWSWIRE
I-Mab Announces the Appointment of Raj Kannan as CEO
22 Jun 2023 //
PR NEWSWIRE
I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with NSCLC
25 May 2023 //
PR NEWSWIRE
I-Mab Announces Poster Presentation CD73 Antibody Uliledlimab at ASCO 2023
26 Apr 2023 //
PR NEWSWIRE
I-Mab Announces Outcome in Arbitration Relating to Agreements with Tracon
25 Apr 2023 //
PR NEWSWIRE
I-Mab Announces First Patient Dosed in Phase 3 Study of Lemzoparlimab
24 Apr 2023 //
PR NEWSWIRE
I-Mab Reports Financial Results for the Year Ended December 31, 2022
31 Mar 2023 //
PR NEWSWIRE
I-Mab to Report Full Year 2022 Financial Results on March 31, 2023
20 Mar 2023 //
PR NEWSWIRE
I-Mab Receives “A” Rating in Updated MSCI ESG Assessment
07 Mar 2023 //
PR NEWSWIRE
I-Mab Announces Two Presentations of CD47 Antibody Lemzoparlimab at ASH 2022
03 Nov 2022 //
PRNEWSWIRE
I-Mab to Present CD47 Antibody Lemzoparlimab & CD73 Antibody Uliledlimab
05 Oct 2022 //
PRNEWSWIRE
I-Mab Announces Approval to Initiate PIII Study of Lemzoparlimab & Azacitidine
13 Sep 2022 //
PRNEWSWIRE
I-Mab Announces Positive Phase 2 Data of Lemzoparlimab with Azacitidine
11 Sep 2022 //
PRNEWSWIRE
I-Mab to Present PII Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022
06 Sep 2022 //
PRNEWSWIRE
I-Mab Reports Financial Results for the Six Months Ended June 30, 2022
30 Aug 2022 //
PRNEWSWIRE
China and US consider possible solution for US-listed companies
25 Aug 2022 //
ENDPTS
I-Mab Announces Share Purchase Plans by the Company and the Senior Management
23 Aug 2022 //
PRESS RELEASE
I-Mab to Report Financial Results for the Six Months
19 Aug 2022 //
PRNEWSWIRE
AbbVie calls off PI trial for I-Mab’s CD47 after Zai Lab shelves program
17 Aug 2022 //
ENDPTS
I-Mab Begins Dosing in PI Trial of Claudin 18.2 and 4-1BB Bispecific Ab TJ-CD4B
22 Jul 2022 //
PRNEWSWIRE
BMS vets tie up another all-stock deal
21 Jul 2022 //
ENDPTS
AbbVie terminates early-stage study of I-Mab`s antibody
21 Jul 2022 //
ENDPTS
I-Mab to Present PII Data of CD47 Ab Lemzoparlimab at ESMO 2022
18 Jul 2022 //
PRESS RELEASE
I-Mab to Host 2022 R&D Day
06 Jul 2022 //
PRNEWSWIRE
I-Mab Receives Top Rankings in Five Categories by Institutional Investor
23 Jun 2022 //
PRNEWSWIRE
I-Mab Partner MorphoSys Announces License Agreements for Felzartamab and TJ210
15 Jun 2022 //
PRNEWSWIRE
Genexine Completes Enrollment in PIII Trial with GX-H9/TJ101
14 Jun 2022 //
BIOSPACE
I-Mab concludes subject enrolment in Phase III PGHD treatment trial
01 Jun 2022 //
CLINICALTRIALSARENA
I-Mab Completes Patient Enrollment in PIII Trial of Eftansomatropin alfa
31 May 2022 //
PRNEWSWIRE
I-Mab, Junshi`s cancer combo worked best as first-line treatment
28 May 2022 //
FIERCEBIOTECH
I-Mab Reports Latest PII Data of its Differentiated CD73 Antibody Uliledlimab
27 May 2022 //
ASIAONE
I-Mab to Hold Investor Call to Report Latest PII Data of Uliledlimab
19 May 2022 //
PRNEWSWIRE
I-Mab Provides Updates on Status under Holding Foreign Companies Accountable Act
05 May 2022 //
PRNEWSWIRE
Chinese biotech I-Mab spikes on report of buyout interest (updated)
03 May 2022 //
SEEKING ALPHA
